一项一线化疗采用每周卡铂联合吉西他滨治疗晚期非小细胞肺癌的 II 期研究。

A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.

机构信息

Division of Thoracic Oncology, Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan.

出版信息

Chemotherapy. 2012;58(1):78-83. doi: 10.1159/000335601. Epub 2012 Feb 23.

DOI:10.1159/000335601

PMID:22377616

Abstract

BACKGROUND

The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC).

METHODS

46 chemotherapy-naive patients with measurable NSCLC were enrolled. Patients underwent a combination chemotherapy of GEM 1,000 mg/m2 plus CBDCA at an area under the curve of 2 on days 1 and 8 every 3 weeks.

RESULTS

Response rate was 30% (14/46; 95% confidence interval: 17.7-45.8%). The median number of treatment cycles was 3 (range 1-2). Time to progressive disease was 19.4 weeks and the median survival was 46.3 weeks. The 1-year survival rate was 46.9%. The major toxicity was hematotoxicity: grade 3 or 4 neutropenia (58.7%) and thrombocytopenia (45.7%). There were no other severe toxicities.

CONCLUSION

Weekly chemotherapy with CBDCA plus GEM is a well-tolerated and promising regimen as first-line treatment of advanced NSCLC.

摘要

背景

每周卡铂（CBDCA）联合吉西他滨（GEM）作为一线治疗晚期非小细胞肺癌（NSCLC）的疗效和安全性已得到评估。

方法

46 例初治的可测量 NSCLC 患者入组。患者接受吉西他滨 1000mg/m2 联合 CBDCA 曲线下面积 2，于第 1 和第 8 天，每 3 周 1 次的联合化疗。

结果

有效率为 30%（14/46；95%置信区间：17.7-45.8%）。中位治疗周期数为 3（范围 1-2）。疾病进展时间为 19.4 周，中位总生存期为 46.3 周。1 年生存率为 46.9%。主要毒性为血液学毒性：3 或 4 级中性粒细胞减少（58.7%）和血小板减少（45.7%）。无其他严重毒性。